Risk stratification for benign prostatic hyperplasia (BPH) treatment

BJU International

Volumn 107, Issue 6, 2011, Pages 876-880

  Emberton, Mark ^a   Fitzpatrick, John M ^c   Rees, Jon ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b Backwell and Nailsea Medical Group   (United Kingdom)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

BPH; Combined therapy; Risk stratification

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

COMBINATION CHEMOTHERAPY; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; LOWER URINARY TRACT SYMPTOM; MEDICAL SPECIALIST; MONOTHERAPY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; RISK MANAGEMENT; SELF CARE; SHORT SURVEY; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 79952616270     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10041.x     Document Type: Short Survey

References (29)

1. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
2. Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31
3. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15
4. Lieber MM, Rhodes T, Jacobson DJ et al. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int 2010; 105: 214-9
5. National Institute for Health and Clinical Excellence. Lower urinary tract symptoms. The management of lower urinary tract symptoms in men. Clinical Guideline No. 97. May 2010. Available at: http://guidance.nice.org.uk/CG97/ NICEGuidance/pdf/English. Accessed December 2010
6. Brown CT, Van Der Meulen J, Mundy AR, Emberton M. Lifestyle and behavioural interventions for men on watchful waiting with uncomplicated lower urinary tract symptoms: a national multidisciplinary survey. BJU Int 2003; 92: 53-7 (Pubitemid 36843028)
7. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002; 288: 2469-75 (Pubitemid 35340544)
8. Holman H, Lorig K. Patient self-management: a key to effectiveness and efficiency in care of chronic disease. Public Health Rep 2004; 119: 239-43 (Pubitemid 38868447)
9. Brown CT, Yap T, Cromwell DA et al. Self-management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007; 334: 25-8 (Pubitemid 46095444)
10. Inglis SC, Clark RA, McAlister FA et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010; 8: CD007228
11. Hainsworth J, Barlow J. Volunteers' experiences of becoming arthritis self-management lay leaders: "It's almost as if I've stopped aging and started to get younger!". Arthritis Rheum 2001; 45: 378-83
12. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51: 207-16 (Pubitemid 44821521)
13. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734-41 (Pubitemid 43383505)
14. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185-91
15. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2008; 62: 18-26 (Pubitemid 350294023)
16. Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006; 60: 1157-65 (Pubitemid 44363649)
17. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600 (Pubitemid 26023551)
18. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36 (Pubitemid 28136681)
19. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008; 101 (Suppl. 3): 17-21 (Pubitemid 351328802)
20. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245-50 (Pubitemid 34134525)
21. Roberts RO, Jacobsen SJ, Jacobsen DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163: 107-13
22. Roehrborn CG, McConnell J, Bonilla J et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163: 13-20
23. Jacobsen SJ, Jacobsen DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7 (Pubitemid 27327692)
24. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999; 162: 376-82 (Pubitemid 29434344)
25. Vallancien G, Emberton M, Alcaraz A et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008; 101: 847-52 (Pubitemid 351347733)
26. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006; 97 (Suppl. 2): 12-5 (Pubitemid 43356989)
27. National Clinical Guideline Centre. The management of lower urinary tract symptoms in men. R Coll Physicians, 2010
28. Kirby R, Kirby M, Fitzpatrick J, Fitzpatrick A. Shared Care for Prostatic Disease. Oxford: ISIS Medical Media Ltd, 1994
29. Naslund M, Black L, Eaddy M, Batiste LR. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. Am J Manag Care 2007; 13 (Suppl. 1): S17-22